Hormone Tests During Perimenopause: What to Test and How to Understand the Results

Published on: ⋄10 min read
Author: Valeriia Voronova, Editor at SOD Energy
A single blood test reflects only one moment in the menopausal transition

Hot flashes have appeared, periods have become irregular, yet FSH and estradiol on the lab report fall within the reference range. This can happen during perimenopause. The European Society of Endocrinology recommends that in generally healthy women over 45, perimenopause be identified primarily by symptoms and changes in the menstrual cycle: a one-off hormone panel rarely provides information that changes a doctor’s decision.

At a younger age, after certain types of treatment, or when symptoms are atypical, tests may be necessary. Their value depends on the question: ruling out another cause of missed periods, checking ovarian function, or assessing the safety of treatment that has already been prescribed. There is no universal “perimenopause panel.”

Why Hormone Levels Are Hard to Assess With a Single Test During Perimenopause

Perimenopause spans the years when ovarian function changes before the final menstrual period and the first year after it. Menopause itself is usually identified retrospectively: after 12 months without periods, provided the absence of bleeding is not explained by another cause. This benchmark may not apply during hormone therapy or contraception.

As the number of follicles decreases, feedback between the ovaries and pituitary gland changes. The pituitary releases more follicle-stimulating hormone, or FSH, which stimulates follicle growth. However, the remaining follicles can still produce estradiol actively. The transition to menopause, then, does not look like a steady decline in estrogen.

Some cycles occur with ovulation, others without it. Progesterone production after ovulation may also change. FSH, luteinizing hormone, or LH, and estradiol vary from day to day, between phases, and across cycles. This does not mean that all three levels necessarily change dramatically within a single day in every woman.

Studies that collected samples frequently illustrate this variability. In a 1996 study by Nanette Santoro and colleagues, researchers compared data from 11 women aged 43 and older with data from 11 women aged 19–38. The older group had higher average urinary excretion of estrone conjugates. These are estrogen metabolites in urine, not estradiol levels in blood. The findings of this small study should not be turned into the claim that “everyone has twice as much estrogen during perimenopause.”

In a 2007 study by Hale and colleagues, 76 participants had blood drawn three times a week over the course of one cycle. When comparing stages of reproductive aging during ovulatory cycles, the researchers found higher FSH, LH, and estradiol, lower progesterone in the second phase, and a decline in AMH. The authors compared groups at different stages; they did not follow each participant through to menopause. The study helps explain why estradiol may remain stable or rise early in the transition.

Hormone levels also do not always correspond to the severity of hot flashes, sleep problems, and other symptoms. This limitation is specifically noted in the 2026 VA/DOD guideline. Symptoms are part of the broader range of changes in the body during menopause that cannot be captured by a single blood test.

When Hormone Tests Are Actually Needed

Age and the pattern of changes determine the scope of testing. The 2025 European Society of Endocrinology guidelines recommend the following approach.

Situation

Role of hormone tests

Over 45, with typical symptoms and changes in menstruation

Usually not needed to confirm perimenopause. Assessment is based primarily on symptoms and menstrual history.

Aged 40–45, with symptoms and menstrual irregularities

A doctor may order tests of ovarian function if the results could help clarify the diagnosis and next steps.

Under 40, with infrequent or absent periods and symptoms of estrogen deficiency

Testing is needed when premature ovarian insufficiency is suspected. Do not delay evaluation by dismissing everything as “early menopause.”

The rule that “hormone tests are usually unnecessary after 45” applies to a typical clinical picture. It does not rule out testing for other possible causes of symptoms. If a period is late, pregnancy may need to be ruled out; if symptoms or menstrual irregularities warrant it, a doctor may assess thyroid function and prolactin.

A different approach is needed after treatment that can damage the ovaries, such as certain types of chemotherapy. Menstrual changes also cannot be used as a guide after removal of the uterus. In these cases, the need for tests is determined individually.

It is helpful to clarify in advance what decision will depend on the results. If testing is ordered only to get a “complete hormone profile,” ask what would change if a result were normal, high, or low.

Which Cycle Day to Test FSH and Estradiol

If FSH is actually needed as part of an assessment for perimenopause, the European Society of Endocrinology recommends measuring it on cycle days 2–5 or after more than 40 days without a period. Cycle day 1 is the first day of menstrual bleeding.

The early follicular phase makes it possible to compare results under more similar conditions. But choosing the right day does not eliminate differences between cycles. With irregular bleeding, do not try to find the “perfect date” on your own: timing is chosen according to the purpose of the assessment.

A doctor may order estradiol at the same time to help interpret FSH. In some situations, FSH is repeated after 4–6 weeks if the first result leaves diagnostic uncertainty. This does not mean everyone needs monthly hormone tests.

It is useful to note the cycle day, date of the last period, and medications being taken on the test requisition and alongside the result. Hormonal contraception and menopausal hormone therapy can significantly affect FSH. Do not stop them on your own to prepare for a test: first discuss whether testing is needed at all and how to interpret it while on treatment.

How to Understand FSH, Estradiol, and LH on a Lab Report

A normal FSH does not rule out perimenopause. In a given cycle, the ovaries may produce enough estradiol to suppress FSH through feedback. The balance may be different in another cycle.

An FSH level above 25 IU/L in the early follicular phase, or when periods are infrequent or absent, supports the possibility of perimenopause. However, there is no universal diagnostic threshold. The result is assessed alongside age, menstrual history, estradiol, and medications. It cannot determine the date of the final menstrual period.

The same caution applies to estradiol. A low level may correspond to reduced ovarian activity at the time the blood was drawn. A normal or high level does not rule out the transition to menopause. In addition, laboratory reference ranges depend on the cycle phase and measurement method: the word “normal” does not mean the cause of symptoms has been established.

LH is involved in regulating ovulation and also changes during the cycle. Adding it to FSH and estradiol does not turn a one-off panel into a reliable “menopause clock.” It is usually unnecessary to measure all three routinely just to confirm typical perimenopause.

When considering menopausal hormone therapy, a doctor takes into account symptoms, medical history, contraindications, and the woman’s preferences. The goal of treatment is not simply to reach a particular estradiol or FSH number.

Interpreting hormone test results in light of the menstrual cycle and medications
Age, menstrual history, cycle day, and medications are all important when assessing a result. The lab report alone does not contain all this information.

Can AMH Predict When Menopause Will Occur?

Anti-Müllerian hormone, or AMH, is produced by cells in small, developing follicles. Its level is associated with ovarian reserve and tends to decline as reproductive aging progresses. For this reason, AMH is being studied as a possible way to predict the timing of the final menstrual period.

In an analysis of SWAN published by Finkelstein and colleagues in 2020, researchers studied more than 7,400 blood samples from 1,537 women. Models using AMH distinguished more accurately than models using FSH which women would have their final menstrual period within the next 24 months.

But the result depended on age. With an AMH level below 10 pg/mL, the likelihood of the final menstrual period occurring within the next 12 months was 51% in women under 48 and 79% in women aged 51 and older. The same concentration gave a substantially different prediction. Even in the older group, the event did not occur within a year for everyone.

SWAN used an ultrasensitive method to measure AMH. Its thresholds cannot automatically be applied to results from another laboratory: the test’s sensitivity and the details of the prediction model matter.

A 2023 systematic review by Nelson and colleagues combined 41 studies involving nearly 29,000 women. Lower AMH was associated with earlier menopause, but individual predictions remained imprecise. Prediction intervals were especially wide for women under 40.

In other words, AMH can improve a probabilistic estimate in certain circumstances, but it cannot reliably identify an individual’s personal date of menopause. It does not replace the standard benchmark of 12 months without periods and is usually unnecessary to diagnose typical perimenopause after age 45. A low result on its own is also not a reason to start hormone therapy.

Why Testosterone Is Tested in Women and What Clinical Trials Show

Testosterone is often added to testing when someone is experiencing fatigue, lower libido, or is interested in maintaining muscle mass. However, a lab result does not automatically explain any of these symptoms. There is no diagnostic threshold for total testosterone in hypoactive sexual desire disorder.

Small trials often cited in support of “testosterone replacement” studied different groups of women and different doses.

  • In a 2014 trial by Huang and colleagues, 71 postmenopausal women who had undergone hysterectomy and were receiving estradiol were randomized. Over 24 weeks, significant gains in lean body mass and certain measures of muscle power compared with placebo were found only at the highest dose. This dose produced testosterone concentrations about 5–6 times above physiological levels. This finding does not prove that safe, physiological doses benefit muscle during perimenopause.

  • A 1995 study by Davis and colleagues included 34 postmenopausal women. Adding testosterone to estradiol was associated with a greater increase in bone mineral density across several measurements over two years. The study was small and single-blind; it did not assess a reduction in fractures.

  • In a 2003 trial by Goldstat and colleagues, complete data were obtained from 31 women with low libido, regular cycles, and an average age of about 40. Measures of sexual function and overall psychological well-being improved. The change in depression scores did not reach statistical significance. These findings should not be presented as proven treatment for depression or as a general recommendation for perimenopause.

The best-supported use of testosterone is for hypoactive sexual desire disorder in postmenopausal women after a comprehensive assessment. A doctor considers pain, medications, mood, relationships, and other possible causes. The 2021 ISSWSH guidelines also allow therapy to be considered in later reproductive life for this disorder, while emphasizing that evidence is limited.

When treatment is prescribed, total testosterone is used primarily to prevent excessive dosing. It is checked before treatment begins and 3–6 weeks after starting. This is not a search for a universal “optimal” level for energy, mood, or youthfulness.

Possible side effects include acne and increased hair growth; excessive doses can cause signs of virilization, including voice changes. The small trials listed above cannot establish long-term safety.

A detailed personal diary with numerous measurements also cannot establish whether treatment is effective. Without a control group, it is impossible to reliably separate the effects of the hormone from exercise, nutrition, other medications, and natural fluctuations in well-being. Reports of improvement or side effects can be useful prompts for questions to a doctor, but they are not grounds for prescribing treatment on your own.

What to Prepare Before Your Doctor’s Appointment

A history of changes is often more useful than a random hormone panel. Before your appointment, it is worth collecting:

  • The dates your periods started and the length of your cycles, including unusually long gaps.

  • Details about bleeding: whether it has become heavier or started occurring between periods.

  • Your symptoms and how they affect your life: hot flashes, night sweats, sleep problems, vaginal dryness, and mood changes.

  • A list of medications and hormonal products, including contraception, with doses and start dates.

  • Previous test results, with dates, cycle days, and units of measurement.

Together with your doctor, you can decide whether FSH testing is needed, whether another cause of symptoms should be ruled out, or whether there is already enough information to discuss support and treatment. A mismatch between how you feel and a single test result does not, by itself, mean that more tests are needed.

Bleeding between periods, after sex, or after 12 months without periods requires a separate assessment. Very heavy bleeding accompanied by weakness, dizziness, or fainting calls for urgent medical care: a hormone panel will not resolve that situation.

Does low AMH mean pregnancy is no longer possible?

No. Low AMH alone does not mean pregnancy is impossible. It is associated with ovarian reserve, but it does not determine whether ovulation will occur in a particular cycle. Do not decide to stop using contraception based on AMH alone.

How is perimenopause assessed after a hysterectomy?

If the ovaries are still in place, removal of the uterus alone does not mean menopause has occurred. A doctor considers age, symptoms, the circumstances of the surgery, and orders tests if needed. The benchmark of 12 months without periods does not apply here because bleeding is absent for another reason.

Is progesterone needed to confirm perimenopause?

Usually not: a one-off progesterone test neither confirms nor rules out perimenopause. It may be needed for other clinical questions related to ovulation. In those cases, the timing is chosen in relation to the expected ovulation; a fixed “day 21” does not suit everyone, especially when cycles are irregular.

How was this article?

 

Share

Explore more